In a reversal, Biogen will ask the FDA to approve its Alzheimer's drug
Saturday, November 30, 2019 - 12:25
in Health & Medicine
The decision to advance aducanumab is based on a new look at clinical trial data
Updated by artificial intelligence Tue, 13 Jun 2023, 2:53:47 UTC Learn more
- Tell your friends
- Get science news via